| Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within phase I/II clinical studies based on individual biomarkers of … A Sartore-Bianchi, A Amatu, E Bonazzina, S Stabile, L Giannetta, G Cerea, ... Targeted Oncology 12, 525-533, 2017 | 16 | 2017 |
| Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation? A Amatu, A Sartore-Bianchi, K Bencardino, A Cassingena, F Venturini, ... Current Colorectal Cancer Reports 8, 272-276, 2012 | 2 | 2012 |
| Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within clinical studies based on individual molecular alterations at … A Sartore-Bianchi, A Amatu, S Stabile, F Tosi, E Bonazzina, M Maiolani, ... Annals of Oncology 26, vi39, 2015 | | 2015 |
| Phase II study of dacarbazine for metastatic colorectal cancer: Final results with MGMT analysis. A Amatu, A Sartore Bianchi, C Moutinho, K Bencardino, E Bonazzina, ... Journal of Clinical Oncology 31 (15_suppl), 3581-3581, 2013 | | 2013 |
| Phase II study of dacarbazine for metastatic colorectal cancer with determined MGMT status. A Amatu, A Sartore-Bianchi, K Bencardino, C Moutinho, G Marrapese, ... Journal of Clinical Oncology 30 (15_suppl), 3570-3570, 2012 | | 2012 |
